•
Sep 30, 2024

GE HealthCare Q3 2024 Earnings Report

GE HealthCare reported Q3 2024 financial results with revenue growth of 1% year-over-year and organic revenue growth also at 1%. Net income margin was 9.7%, and adjusted EBIT margin was 16.3%. Diluted EPS was $1.02, and adjusted EPS was $1.14. Cash flow from operating activities reached $742 million, and free cash flow was $651 million. The company raised the low end of its full-year 2024 adjusted EBIT margin and adjusted EPS guidance.

Key Takeaways

GE HealthCare's Q3 2024 results showed a 1% increase in revenue and organic revenue. The company experienced margin expansion and improved earnings per share. They also updated their full-year guidance, raising the low end of adjusted EBIT margin and adjusted EPS expectations.

Revenue growth was 1% year-over-year, with organic revenue growth also at 1%.

Net income margin increased to 9.7% compared to 7.8% in the prior year, while adjusted EBIT margin rose to 16.3% from 15.4%.

Diluted earnings per share (EPS) were $1.02, up from $0.83 in the prior year, and adjusted EPS was $1.14, compared to $0.99.

Cash flow from operating activities was $742 million, up from $650 million, and free cash flow was $651 million, up from $570 million.

Total Revenue
$4.86B
Previous year: $4.82B
+0.9%
EPS
$1.14
Previous year: $0.99
+15.2%
Book-to-Bill
1.04
Previous year: 1.03
+1.0%
Net Income Margin
9.7%
Previous year: 7.8%
+24.4%
Adjusted EBIT Margin
16.3%
Previous year: 15.4%
+5.8%
Gross Profit
$2.03B
Previous year: $1.94B
+4.7%
Cash and Equivalents
$3.57B
Previous year: $2.42B
+47.6%
Free Cash Flow
$652M
Previous year: $570M
+14.4%
Total Assets
$33.9B
Previous year: $32.4B
+4.5%

GE HealthCare

GE HealthCare

GE HealthCare Revenue by Segment

Forward Guidance

The Company updates full-year 2024 guidance as follows: •Organic revenue growth* trending toward the lower end of the range of 1% to 2% year-over-year, given the continued China market softness •Adjusted EBIT margin* in the range of 15.8% to 16.0%, reflecting an expansion of 70 to 90 basis points versus 2023 Adjusted EBIT margin* of 15.1%; this compares to prior guidance of 15.7% to 16.0% •Adjusted effective tax rate (ETR)* trending toward the lower end of the 23% to 25% range, given additional tax incentives recognized in third quarter 2024 •Adjusted EPS* in the range of $4.25 to $4.35, representing 8% to 11% growth versus Adjusted EPS* of $3.93 for 2023; this compares with prior range of $4.20 to $4.35 •Free cash flow* of approximately $1.8 billion

Positive Outlook

  • Organic revenue growth trending toward the lower end of the range of 1% to 2% year-over-year.
  • Adjusted EBIT margin in the range of 15.8% to 16.0%, reflecting an expansion of 70 to 90 basis points versus 2023.
  • Adjusted effective tax rate trending toward the lower end of the 23% to 25% range.
  • Adjusted EPS in the range of $4.25 to $4.35, representing 8% to 11% growth versus Adjusted EPS of $3.93 for 2023.
  • Free cash flow of approximately $1.8 billion.

Challenges Ahead

  • Organic revenue growth trending toward the lower end of the range due to continued China market softness.
  • Uncertainty regarding the precise impact of global economic factors.
  • Potential fluctuations in currency exchange rates.
  • Impacts associated with potential business acquisitions or dispositions.
  • Unpredictable timing and magnitude of restructuring activities.

Revenue & Expenses

Visualization of income flow from segment revenue to net income